Inozyme Pharma

Inozyme Pharma is now a wholly owned subsidiary of Pharmaceutical Inc. We look forward to advancing our shared mission in translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient.

Our team is on-site this week at the first ever joint Congress between the European Society for Paediatric Endocrinology ( ) and the European Society of Endocrinology ( ), May 10-13 in Copenhagen. We contributed to a presentation on the evaluation of rickets and are sponsoring a symposium. Come join us!

⚕️Poster Presentation
Quantitative Evaluation of Hypophosphatemic Rickets Due to ENPP1 Deficiency
Leanne Ward, M.D.
Saturday, May 10 | ePoster Session – Bone & Mineral Metabolism -
Multi-center retrospective analysis highlighting persistent FGF23-mediated hypophosphatemia, impaired growth, and delayed bone age in children with ARHR2 under standard of care—underscoring the need for earlier diagnosis and novel therapies.

⚕️Clinical Presentation
Emerging Data in Heterozygous ENPP1 Deficiency
David Weber, M.D., MSCE
New observations suggest monoallelic ENPP1 variants may lead to clinically significant disease - broadening our understanding of ENPP1-related conditions.

⚕️Industry-Sponsored Symposium
Hypophosphatemic Rickets: Practical Tips for Distinguishing ARHR2 from XLH
Sunday, May 11 | 9:55 a.m.
Bella Center, Copenhagen
Led by Dr. Lothar Seefried, the session focused on diagnostic clarity and actionable strategies to improve patient outcomes.

Let’s connect while we’re here!